<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48551">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01858428</url>
  </required_header>
  <id_info>
    <org_study_id>TP-1397</org_study_id>
    <nct_id>NCT01858428</nct_id>
  </id_info>
  <brief_title>ILLUMENATE Pivotal, CVI Drug-coated Balloon vs. Uncoated Balloon</brief_title>
  <acronym>ILLUMENATE Piv</acronym>
  <official_title>ProspectIve, Randomized, SingLe-Blind, U.S. MuLti-Center Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Covidien</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Covidien</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to demonstrate safety and efficacy of a Paclitaxel-coated
      percutaneous transluminal angioplasty (PTA) Catheter to treat peripheral arterial disease.
      There are two hypotheses being tested. 1) The drug-coated PTA catheter is as safe as the PTA
      catheter without drug and 2)The drug-coated PTA catheter is more effective than the catheter
      without drug.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Patency at 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patency at 12 months post-procedure.  Patency is defined as the absence of target lesion restenosis as determined by Duplex Ultrasound (Peak Systolic Velocity Ratio (PSVR) ≤ 2.5) and freedom from clinically-driven target lesion revascularization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from device and procedure-related death through 30 days, TLR 12 months post procedure.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Freedom from device and procedure-related death through 30 days post-procedure and freedom from target limb major amputation and clinically-driven target lesion revascularization through 12 months post-procedure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Bare PTA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control device is a CE-marked, commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien/ev3® Incorporated, Plymouth, MN 55441, USA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug-coated PTA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The CVI Paclitaxel-coated PTA Catheter (CV Ingenuity Corporation/Covidien, Fremont, CA, 94555 USA) is a CE-marked, commercially available PTA balloon catheter (EverCross® 0.035&quot; PTA Balloon Catheter, Covidien/ev3®, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter</intervention_name>
    <arm_group_label>drug-coated PTA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EverCross Percutaneous Transluminal Balloon Catheter</intervention_name>
    <arm_group_label>Bare PTA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with symptomatic leg ischemia, requiring treatment of the Superficial
             Femoral Artery (SFA) or popliteal artery.

        Exclusion Criteria:

          -  Known intolerance to study medications, paclitaxel or contrast agents that in the
             opinion of the investigator cannot be adequately pre-treated
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prakash Krishnan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mt. Sinai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sean Lyden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Cardiac and Vascular Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matheen Khuddus, MD</last_name>
      <phone>352-331-8570</phone>
    </contact>
    <investigator>
      <last_name>Matheen Khuddus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arthur Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Van Roy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>May 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
